Rationale for Targeting TRK Fusions in Solid Tumors and Implementing NTRK Testing in the Clinic

Download this slideset for expert perspectives on current best practices in testing for NTRK fusions in solid tumors.
George D. Demetri, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 798 KB
Released: July 10, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Bayer HealthCare Pharmaceuticals Inc.
Genentech

Related Content

Downloadable slideset with the latest clinical trial data on BTK inhibitors in frontline and relapsed/refractory CLL, from Clinical Care Options (CCO)

Jeff P. Sharman, MD Released: May 7, 2021

Downloadable slideset with pharmacist considerations for the management of CLL using BTK inhibitors, from Clinical Care Options (CCO)

Emily Bucholtz Headshot Emily Bucholtz, RPh Released: May 7, 2021

Downloadable slideset from Sagar Lonial, MD and Kathryn Maples, PharmD, BCOP on treatment options for patients with R/R myeloma, from Clinical Care Options (CCO).

Sagar Lonial, MD Kathryn Maples, PharmD, BCOP Released: May 4, 2021

Download slides from Clinical Care Options (CCO) in which experts provide multidisciplinary insights on the use of checkpoint inhibitors for HCC

Lipika Goyal, MD Amit G. Singal, MD, MS Released: April 30, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue